374 related articles for article (PubMed ID: 37736096)
21. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.
Del Bufalo F; Becilli M; Rosignoli C; De Angelis B; Algeri M; Hanssens L; Gunetti M; Iacovelli S; Li Pira G; Girolami E; Leone G; Lazzaro S; Bertaina V; Sinibaldi M; Di Cecca S; Iaffaldano L; Künkele A; Boccieri E; Del Baldo G; Pagliara D; Merli P; Carta R; Quintarelli C; Locatelli F
Blood; 2023 Jul; 142(2):146-157. PubMed ID: 37172203
[TBL] [Abstract][Full Text] [Related]
22. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
23. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
Front Immunol; 2022; 13():879983. PubMed ID: 35669773
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy.
Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B
J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487
[TBL] [Abstract][Full Text] [Related]
25. Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant.
Li Q; Lyu C; Liu M; Wang J; Mou N; Jiang E; Zhang R; Deng Q
Cell Transplant; 2023; 32():9636897231158155. PubMed ID: 36879459
[TBL] [Abstract][Full Text] [Related]
26. Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
Zhang Y; Chen H; Song Y; Tan X; Zhao Y; Liu X; Li Z; Yang F; Jiang M; Gao Z; Wu T
Br J Haematol; 2020 Apr; 189(1):146-152. PubMed ID: 31869864
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor T Cell Therapy followed by Unrelated Cord Blood Transplantation for the Treatment of Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia in Children and Young Adults: Superior Survival but Relatively High Post-Transplantation Relapse.
Sun G; Tang B; Wan X; Yao W; Song K; Tu M; Geng L; Qiang P; Wu Y; Zhu L; Wu Y; Liu H; Zhu X; Sun Z
Transplant Cell Ther; 2022 Feb; 28(2):71.e1-71.e8. PubMed ID: 34839013
[TBL] [Abstract][Full Text] [Related]
28. Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.
Wang T; Wan X; Yang F; Shi W; Liu R; Ding L; Tang Y; Luo C; Yang X; Ma Y; Wang X; Liang H; Li B; Lu J; Chen J
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):386-392. PubMed ID: 33640284
[TBL] [Abstract][Full Text] [Related]
29. [Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation].
Ai H; Yin QS; Wang Q; Fu YW; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):239-244. PubMed ID: 32311895
[No Abstract] [Full Text] [Related]
30. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia.
Xie L; Ma L; Liu S; Chang L; Wen F
Int Immunopharmacol; 2021 Jul; 96():107731. PubMed ID: 33965880
[TBL] [Abstract][Full Text] [Related]
33. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
Front Immunol; 2022; 13():934442. PubMed ID: 36110859
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
Cao XY; Li JJ; Lu PH; Liu KY
Int J Hematol; 2022 Sep; 116(3):315-329. PubMed ID: 35737192
[TBL] [Abstract][Full Text] [Related]
36. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia].
Tao SD; Song LX; Deng Y; Chen Y; Zhang X; Ding BH; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):677-684. PubMed ID: 37356926
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma.
Fried S; Shouval R; Walji M; Flynn JR; Yerushalmi R; Shem-Tov N; Danylesko I; Tomas AA; Fein JA; Devlin SM; Sauter CS; Shah GL; Kedmi M; Jacoby E; Shargian L; Raanani P; Yeshurun M; Perales MA; Nagler A; Avigdor A; Shimoni A
Transplant Cell Ther; 2023 Feb; 29(2):99-107. PubMed ID: 36343892
[TBL] [Abstract][Full Text] [Related]
39. Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.
Liu J; Zhang X; Zhong JF; Zhang C
Immunotherapy; 2019 Jan; 11(1):37-44. PubMed ID: 30702011
[TBL] [Abstract][Full Text] [Related]
40. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
